Next Article in Journal
COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type
Next Article in Special Issue
Selected Milestones in Antiviral Drug Development
Previous Article in Journal
Covalent Inhibitors from Saudi Medicinal Plants Target RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2
Previous Article in Special Issue
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study

1
Unit of Infectious Disease, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy
2
Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
3
Division of Microbiology and Virology, Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy
*
Author to whom correspondence should be addressed.
Viruses 2023, 15(11), 2180; https://doi.org/10.3390/v15112180
Submission received: 29 September 2023 / Revised: 26 October 2023 / Accepted: 27 October 2023 / Published: 30 October 2023
(This article belongs to the Special Issue Efficacy and Safety of Antiviral Therapy 2nd Edition)

Abstract

Clinical trials demonstrated the role of vaccines and antiviral treatments against SARS-CoV-2 in reducing the likelihood of disease progression and death. However, there are limited data available regarding the time to negativity of people who received these treatments. Further, several comorbidities and risk factors might affect the impact of vaccines and antiviral treatments. To this end, we aimed to evaluate and disentangle the impact of anti-SARS-CoV-2 treatments and that of underlying clinical factors associated with a shortened length of SARS-CoV-2 infection. Hence, we recorded the timeframe of positive nasopharyngeal swab in people infected while being hospitalized for reasons other than SARS-CoV-2 infection. All patients who died or were discharged with a positive swab were excluded from the study. A total of 175 patients were included in this study. Clinical conditions encompass malignancies, immunological disorders, cardiovascular, metabolic, neurodegenerative, and chronic kidney disease. Most of the participants (91.4%) were vaccinated before admission to the hospital, and 65.1% received antiviral treatment within three days after the symptom’s onset. Unvaccinated patients had a longer median time to negativity than people who received at least two doses of vaccine (18 vs. 10 days). Concerning the clinical conditions of all patients, multivariate analysis highlighted a lower probability of 14-day conversion of antigenic test positivity in patients with hematological malignancy, including those vaccinated and those exposed to antiviral therapies. In conclusion, our data showed that prompt administration of antiviral treatments accelerates the clearance of SARS-CoV-2. Further, in the elderly patients under study, previous vaccination and antiviral treatment synergize to reduce time to negativity. This translates into a shorter hospitalization time and a lower risk of transmission through patients and connected healthcare workers in a hospital ward setting, with considerable improvement in cost-effective care management.
Keywords: negativization; COVID-19; antiviral treatment; vaccination; recovery time; monoclonal antibodies; remdesivir; molnupiravir; nirmatrelvir/ritonavir negativization; COVID-19; antiviral treatment; vaccination; recovery time; monoclonal antibodies; remdesivir; molnupiravir; nirmatrelvir/ritonavir

Share and Cite

MDPI and ACS Style

De Vito, A.; Moi, G.; Saderi, L.; Puci, M.V.; Colpani, A.; Firino, L.; Puggioni, A.; Uzzau, S.; Babudieri, S.; Sotgiu, G.; et al. Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study. Viruses 2023, 15, 2180. https://doi.org/10.3390/v15112180

AMA Style

De Vito A, Moi G, Saderi L, Puci MV, Colpani A, Firino L, Puggioni A, Uzzau S, Babudieri S, Sotgiu G, et al. Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study. Viruses. 2023; 15(11):2180. https://doi.org/10.3390/v15112180

Chicago/Turabian Style

De Vito, Andrea, Giulia Moi, Laura Saderi, Mariangela V. Puci, Agnese Colpani, Laura Firino, Anna Puggioni, Sergio Uzzau, Sergio Babudieri, Giovanni Sotgiu, and et al. 2023. "Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study" Viruses 15, no. 11: 2180. https://doi.org/10.3390/v15112180

APA Style

De Vito, A., Moi, G., Saderi, L., Puci, M. V., Colpani, A., Firino, L., Puggioni, A., Uzzau, S., Babudieri, S., Sotgiu, G., & Madeddu, G. (2023). Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study. Viruses, 15(11), 2180. https://doi.org/10.3390/v15112180

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop